Female Pattern Hair Loss (FPHL): Causes, Stages & Treatment Options
Losing hair at your part line? Learn what causes FPHL, how to identify your stage on the Ludwig Scale, and which treatments actually work. Evidence-based guide by Zoey.
At a glance
- If you've noticed your part getting wider, your ponytail feeling thinner, or more hair collecting in the shower drain, you're not imagining it — and you're not alone.
- Female pattern hair loss (FPHL) is the most common cause of hair loss in women worldwide, affecting an estimated 40% of women by age 50 (Sinclair R, 2005, Clinical Dermatology).
- It isn't talked about enough.
Female Pattern Hair Loss (FPHL): Causes, Stages & Treatment Options
If you've noticed your part getting wider, your ponytail feeling thinner, or more hair collecting in the shower drain, you're not imagining it — and you're not alone. Female pattern hair loss (FPHL) is the most common cause of hair loss in women worldwide, affecting an estimated 40% of women by age 50 (Sinclair R, 2005, Clinical Dermatology).
It isn't talked about enough. And because it progresses slowly and without a clear "event" to blame, many women spend years dismissing it before seeking help. This guide covers what FPHL actually is, what's driving it, how to assess your stage, and which treatment options have real evidence behind them.
What Is Female Pattern Hair Loss?
FPHL is a chronic, progressive condition characterised by diffuse thinning over the crown and top of the scalp, while the frontal hairline is largely preserved. Unlike men with androgenetic alopecia — who often develop receding hairlines and bald spots — women typically experience a gradual reduction in hair density that spreads outward from a widening central part.
The condition is androgenetic in origin, meaning it involves both genetic predisposition and the action of androgens (male hormones that all women produce in smaller quantities). However, many women with FPHL have normal androgen levels, which suggests that follicular sensitivity to androgens — not androgen excess — is often the key driver.
What Causes FPHL?
Several factors converge to cause FPHL:
1. Genetics
The single strongest predictor. FPHL runs in families, though it can be inherited from either parent. If your mother, grandmother, or maternal aunts have noticeable thinning, your risk is elevated. That said, genetics is not destiny — early intervention matters.
2. Androgen Sensitivity
Dihydrotestosterone (DHT), a byproduct of testosterone, binds to receptors in hair follicles and progressively shortens the anagen (growth) phase. Over successive cycles, follicles miniaturise — producing thinner, shorter, less pigmented hairs — until growth stops entirely in affected zones. Women with FPHL often have follicles that are more sensitive to DHT, even when serum androgen levels fall within the normal range.
3. Hormonal Transitions
Oestrogen acts as a natural counterbalance to androgens. When oestrogen drops — at perimenopause, post-pregnancy (postpartum shedding), or after stopping oral contraceptives — androgens' relative effect on follicles increases, and FPHL often accelerates.
4. Micronutrient Deficiencies
Iron deficiency (ferritin below 30–40 ng/mL), low Vitamin D, and suboptimal zinc are consistently found in women presenting with increased shedding. They are rarely the primary cause of FPHL, but they are common amplifiers that can be addressed.
5. Chronic Stress
Sustained physiological or psychological stress elevates cortisol, which disrupts the hair growth cycle and can trigger or worsen diffuse shedding (telogen effluvium) — a condition that frequently co-exists with and complicates FPHL.
The Ludwig Scale: Staging Your Hair Loss
The Ludwig Classification (Ludwig, 1977) is the most widely used system for grading FPHL severity. It describes three stages:
| Stage | What It Looks Like |
|---|---|
| Ludwig I | Slight thinning at the crown; part line is visibly wider. Hair volume may feel reduced. Most people notice this only in photos or when styling. |
| Ludwig II | Pronounced thinning at the crown with significant widening of the part. The scalp is visible under bright light or when hair is parted. |
| Ludwig III | Extensive thinning across the crown creating near-total transparency at the top. The frontal hairline is usually retained but hair density is severely reduced. |
Early-stage detection (Ludwig I) is the best time to intervene. Follicles that have miniaturised but are not yet dormant can still respond to treatment. Once a follicle has been inactive for an extended period, recovery is significantly harder.
The Sinclair Scale (Sinclair R, 2005) is a five-point photographic scale that offers finer gradation and is increasingly preferred in clinical research for measuring treatment response in women.
Treatment Options: What the Evidence Supports
There is no single cure for FPHL, but there are multiple evidence-backed interventions that can slow progression, stabilise shedding, and in many cases produce visible regrowth. Treatments work best when started early and sustained consistently.
Topical Minoxidil
The only topical treatment approved by the US FDA for female pattern hair loss. Minoxidil prolongs the anagen phase and increases follicle size. In randomised controlled trials, 5% minoxidil solution applied once daily produced statistically significant increases in hair count versus placebo (Olsen EA et al., 2002, JAAD). Common formulations include 2% and 5% solutions or 5% foam. Consistent daily use is required — response typically becomes visible at 3–6 months and stops if treatment is discontinued.
Oral Minoxidil (Low-Dose)
Low-dose oral minoxidil (0.25–1mg/day) is increasingly used off-label and in clinical practice as an alternative for women who experience scalp irritation from topical formulations. A 2021 systematic review in JAAD found comparable or superior efficacy to topical forms, with a favourable tolerability profile at low doses.
Anti-Androgen Therapy
For women with confirmed hyperandrogenism or significant hormonal FPHL, anti-androgens such as spironolactone or cyproterone acetate may be prescribed. These are prescription-only medications requiring medical assessment. They are not appropriate during pregnancy.
Platelet-Rich Plasma (PRP)
PRP involves drawing a small amount of the patient's blood, concentrating the growth factor-rich plasma via centrifugation, and injecting it into the scalp. Multiple small RCTs and a 2019 meta-analysis (Dermatologic Surgery) support improvements in hair density and thickness. It is typically administered as a series of 3 sessions, then quarterly maintenance.
Low-Level Laser Therapy (LLLT)
Devices cleared by regulatory authorities (FDA, HSA) for hair growth use photobiomodulation to stimulate follicular activity. Evidence supports modest improvements in hair density with consistent use (Lanzafame RJ et al., 2013, Lasers in Surgery and Medicine).
Nutritional Support
Addressing deficiencies in ferritin, Vitamin D, zinc, and biotin is a low-risk adjunct to primary treatment. Targeted supplementation is most useful where a confirmed deficiency exists.
What Doesn't Work (Or Doesn't Have Enough Evidence)
- Caffeine shampoos: Mechanistically plausible, minimal human trial data.
- Keratin treatments and scalp serums without active ingredients: Cosmetic, not therapeutic.
- Hair transplants as a standalone solution: Can provide excellent cosmetic results for appropriate candidates but do not stop the underlying progression — medical treatment is still required post-transplant.
When to See a Doctor
See a doctor or trichologist if:
- You're shedding more than 100–150 hairs per day consistently
- Thinning has progressed rapidly over weeks rather than months
- You have associated symptoms (irregular periods, acne, unexpected weight changes) that may suggest a hormonal condition
- Over-the-counter approaches have not stabilised shedding after 6 months
Blood panels worth requesting: ferritin, full blood count, thyroid function (TSH, fT4), fasting insulin, DHEAS, testosterone, and Vitamin D.
Frequently Asked Questions
Can FPHL be reversed?
Partial reversal is possible, especially in early stages. Treatment can halt progression and stimulate regrowth of miniaturised (not yet dormant) follicles. Full density restoration is rarely achievable, which is why early action matters.
Is FPHL the same as alopecia areata?
No. Alopecia areata is an autoimmune condition causing patchy bald spots with a distinct mechanism and treatment pathway. FPHL is diffuse and androgenetic in origin.
How long before I see results from minoxidil?
Typically 3–6 months of consistent use. Some women experience initial increased shedding in weeks 1–6 as follicles transition — this is normal and resolves.
Does stress cause FPHL?
Stress does not directly cause FPHL but can trigger telogen effluvium (acute diffuse shedding) and accelerate underlying FPHL in genetically predisposed women.
Is FPHL related to menopause?
Yes. Declining oestrogen at perimenopause reduces its protective counterbalance to androgens, often causing FPHL to accelerate or become noticeable for the first time in women in their late 40s–50s.
The Earlier You Act, The More You Have to Work With
FPHL is a progressive condition — but progress is not inevitable if you intervene. The women who maintain density long-term are almost always those who identified the signs early and built a consistent treatment routine before significant follicle loss occurred.
If you're noticing the early signs — a wider part, reduced volume, more hair in the brush — now is the right time to act.
Take Zoey's hair assessment →
Find out your likely stage and get a personalised protocol from Zoey's clinical team.
References
- Ludwig E. (1977). Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. British Journal of Dermatology, 97(3), 247–254.
- Sinclair R. (2005). Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. International Journal of Dermatology, 44(Suppl 1), 43–45.
- Olsen EA, et al. (2002). A randomised clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology, 47(3), 377–385.
- Gupta AK, Bamimore MA. (2021). Oral minoxidil for alopecia: a systematic review. Journal of the American Academy of Dermatology, 85(6), 1557–1560.